Weekly Plasma Summary - November 23, 2024

This week in the global plasma market, we saw a slight uptick in daily performance, with the sector-weighted price increasing by 0.72% to $104.86. However, the 7-day trend shows a minor -0.41% decline, reflecting mixed performances among key players. Today’s total market volume: $6.7 million, with a total market cap of $164 billion.

Company Highlights

1. Top Performers:

   • Cerus Corp surged by 7.19% over both daily and 7-day periods.

   • ADMA Biologics Inc delivered a robust 8.39% 7-day gain, continuing its upward momentum from prior weeks.

   • China Resources Boya Bio posted a notable 3.94% 7-day increase.

2. Underperformers:

   • Grifols SA saw a -5.64% decline over 7 days.

   • Haemonetics Corporation saw a moderate -2.97% weekly drop.

3. Steady Performers:

   • CSL Ltd maintained its growth trajectory with a 1.48% 7-day gain.

   • GC Biopharma Corp delivered consistent gains, rising 2.75% over 7 days.

Top 3 Headlines

1. Grifols Rejects $6.8 Billion Buyout Bid from Brookfield, Citing Undervaluation

2. Alloy Therapeutics and Takeda Forge Partnership to Advance Off-the-Shelf iCAR-T and iCAR-NK Cancer Therapies. 

3. ADMA Biologics CEO Sells $1M in Shares as Company Reports Explosive Growth and Bold Expansion Plans

Plasma 101

Plasma contains clotting factors, such as fibrinogen, which are essential for stopping bleeding and promoting wound healing.